{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:23:12Z","timestamp":1782814992389,"version":"3.54.5"},"reference-count":36,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T00:00:00Z","timestamp":1736035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100021510","name":"Department of Haematology, Christian Medical College, Vellore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005275","name":"Region Hovedstaden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Despite advances in treatment, approximately 15% of patients with diffuse large B\u2010cell lymphoma (DLBCL) who achieve complete remission (CR) after first\u2010line therapy will experience a relapse. However, there is no consensus on the optimal follow\u2010up strategies for detecting relapse after achieving CR. This population\u2010based study, based on the Danish Lymphoma Registry (LYFO), identified a total of 1634 patients diagnosed with DLBCL between 2010 and 2017, including 105 patients who achieved CR following first\u2010line R\u2010CHOP\u2010like therapy and subsequently relapsed. The median follow\u2010up time was 6\u2009years (range 3\u20138\u2009years). Most cases of relapse were symptomatic (83%), with B symptoms and peripheral lymphadenopathy being the most common. Asymptomatic relapses were identified through physical examination (1%), blood tests (3%), or imaging findings (13%). The proportion of relapses identified outside routine visits was 70%. Only 5% of scheduled routine visits led to a relapse diagnosis, whereas 74% of unscheduled visits initiated by the patient outside routine follow\u2010up resulted in relapse detection. Our findings highlight that systematic, scheduled monitoring of patients in remission after first\u2010line treatment contributes only modestly to the early detection of disease recurrence. Future studies should explore alternative methods of relapse surveillance rather than relying solely on pre\u2010scheduled clinical follow\u2010up.<\/jats:p>","DOI":"10.1002\/ajh.27577","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T01:39:56Z","timestamp":1736127596000},"page":"408-416","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Limited Benefit of Routine Clinical Follow\u2010Up for Relapse Detection in Diffuse Large B\u2010Cell Lymphoma Patients in Complete Remission Following First\u2010Line Treatment"],"prefix":"10.1002","volume":"100","author":[{"given":"Therese","family":"Lassen","sequence":"first","affiliation":[{"name":"Department of Hematology Rigshospitalet  Copenhagen Denmark"},{"name":"Cancer Survivorship and Treatment Late Effects (CASTLE) \u2010 Danish Cancer Society National Research Center, Department of Oncology Copenhagen University Hospital, Rigshospitalet  Copenhagen Denmark"},{"name":"Department of Clinical Medicine University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten H.","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Hematology Rigshospitalet  Copenhagen Denmark"},{"name":"Danish Medicines Agency  Copenhagen Denmark"},{"name":"Deparment of Hematology Zealand University Hospital  Roskilde Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"von Heymann","sequence":"additional","affiliation":[{"name":"Cancer Survivorship and Treatment Late Effects (CASTLE) \u2010 Danish Cancer Society National Research Center, Department of Oncology Copenhagen University Hospital, Rigshospitalet  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene K.","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Quality of Life Research Center, Department of Hematology, Odense University Hospital, Odense, Denmark and Department of Clinical Research University of Southern Denmark  Odense Denmark"},{"name":"Department of Hematology G\u00f8dstrup Hospital  Herning Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten K.","family":"Larsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine University of Copenhagen  Copenhagen Denmark"},{"name":"Deparment of Hematology Zealand University Hospital  Roskilde Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne O.","family":"Gang","sequence":"additional","affiliation":[{"name":"Department of Hematology Rigshospitalet  Copenhagen Denmark"},{"name":"Department of Clinical Medicine University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer","family":"Johansen","sequence":"additional","affiliation":[{"name":"Cancer Survivorship and Treatment Late Effects (CASTLE) \u2010 Danish Cancer Society National Research Center, Department of Oncology Copenhagen University Hospital, Rigshospitalet  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9419-8841","authenticated-orcid":false,"given":"Lars M.","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine University of Copenhagen  Copenhagen Denmark"},{"name":"Deparment of Hematology Zealand University Hospital  Roskilde Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,5]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.1747"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.04.013"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13420"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.0765"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00538-7"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301665"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_11_12_1","first-page":"559","article-title":"Follow\u2010Up Strategies Following Completion of Primary Cancer Treatment in Adult Cancer Survivors","volume":"2019","author":"H\u00f8eg B. L.","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.0229"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.7.1196"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.7561"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14745"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23688"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2021.1975957"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv304"},{"key":"e_1_2_11_21_1","unstructured":"\u201cNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) B\u2010Cell Lymphomas Version 2 \u201d2024."},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14136"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157999"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S91125"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_11_28_1","unstructured":"U.S. Department of Health and Human Services \u201cCommon Terminology Criteria for Adverse Events (CTCAE) Version 5.0 \u201d2017 https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01931-2"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.11.024"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.5866"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.04.007"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01618-w"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70106-3"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.925366"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2017.03.002"},{"key":"e_1_2_11_37_1","first-page":"1","article-title":"Sexual Dysfunction Is Highly Prevalent in Male Survivors of Malignant Lymphoma","volume":"11","author":"Pedersen S. M.","year":"2023","journal-title":"Sexual Medicine"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.27577","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T10:09:52Z","timestamp":1754906992000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.27577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,5]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1002\/ajh.27577"],"URL":"https:\/\/doi.org\/10.1002\/ajh.27577","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,5]]},"assertion":[{"value":"2024-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}